Allergan recalls textured breast implants in Canada

Issue: BCMJ, vol. 61 , No. 6 , July August 2019 , Pages 246-247 News

Allergan Canada is voluntarily recalling textured breast implants from the Canadian market as a result of Health Canada’s suspension of the Biocell textured implant licence. As part of this voluntary recall, any unused Biocell saline-filled and silicone-filled textured breast implants (medical device licences 3112, 72262, 72263, 87277, and 87279) will be removed from the Canadian market and no longer be sold. Natrelle smooth implants and tissue expanders are not impacted by this licence suspension and voluntary recall.

Patients are advised to discuss the risks and benefits of their implant type with their plastic surgeon should they have any concerns. There continues to be no recommendation from Health Canada for asymptomatic patients to have their textured breast implants removed or replaced prophylactically. Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) has been reported in patients with an implant history that includes Allergan’s and other manufacturers’ textured breast implants with various surface properties, styles, and shapes.

If you have questions about Biocell textured breast implants, contact the medical information team at MR-MedicalInformation@Allergan.com or 1 800 668-6424, and visit Allergan’s website at www.allergan.com. For more information about Health Canada’s recall and safety alert visit www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/69520a-eng.php.

. Allergan recalls textured breast implants in Canada. BCMJ, Vol. 61, No. 6, July, August, 2019, Page(s) 246-247 - News.



Above is the information needed to cite this article in your paper or presentation. The International Committee of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

About the ICMJE and citation styles

The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.

An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.

BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:

  • Only the first three authors are listed, followed by "et al."
  • There is no period after the journal name.
  • Page numbers are not abbreviated.


For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org

BCMJ Guidelines for Authors

Leave a Reply